Evidence map›Paper›PMID 41144016›Full record

ArticleUrolithiasis2025

Comparison of 24-Hour urine parameters before and after initiation of Metformin in patients with diabetes and urolithiasis: A retrospective analysis.

Taylor Crook, Ian Ong, Yezan Hadidi, Aymon Ali, John M Hollingsworth, Mary K Oerline, Vahakn B Shahinian, Sara Best, Ryan S Hsi, Joseph J Crivelli and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Taylor CrookDepartment of Urology, University of California,, Irvine - Orange, CA, USA. tcrook@hs.uci.edu.
Ian OngDepartment of Urology, University of California,, Irvine - Orange, CA, USA.
Yezan HadidiDepartment of Urology, University of California,, Irvine - Orange, CA, USA.
Aymon AliDepartment of Urology, University of California,, Irvine - Orange, CA, USA.
John M HollingsworthDepartment of Urology, University of Florida College of Medicine,, Gainesville, USA.
Mary K OerlineDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Vahakn B ShahinianDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Sara BestDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Ryan S HsiDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Joseph J CrivelliDepartment of Urology, University of Alabama at Birmingham, AL , Birmingham, United States of America.
Ralph V ClaymanDepartment of Urology, University of California,, Irvine - Orange, CA, USA.

Funding

Endourological Society Endourology Society Summer Scholarship
6 · The paper itself

Abstract

This retrospective study investigated the impact of metformin initiation on 24-hour urine parameters in patients with diabetes with urolithiasis. Utilizing the Medicare-Litholink database, we analyzed 427 patients who started metformin between two 24-hour urine collections conducted less than 18 months apart. To isolate the effect of metformin on urinary parameters as a surrogate marker of stone growth, we excluded patients taking other oral hypoglycemics or medications known to alter urine composition. Our longitudinal analysis revealed no statistically significant changes in key urinary parameters, including supersaturation of calcium oxalate, supersaturation calcium phosphate, and supersaturation of uric acid. Urine volume showed a significant, albeit clinically minor, increase (2.1 to 2.2 L/day, p = 0.0074). Time-dependent analysis comparing short-term (< 100 days) and long-term (> 296 days) metformin use also showed no significant impact on urine chemistry. Similarly, when controlling dosage of metformin ([Formula: see text]1000 mg/day or > 1000 mg/day) we found no significant impact on urine chemistry. These findings suggest that metformin use is not significantly associated with reduced urinary stone risk factors in patients with diabetes and urolithiasis, thus, failing to support its use among urolithiasis patients with new onset diabetes.

Indexed as

Diabetes MellitusHypoglycemic AgentsMetforminUrolithiasisAgedAged, 80 and overCalcium OxalateCalcium PhosphatesFemaleHumansMaleMiddle AgedRetrospective StudiesUric AcidCalcium OxalateCalcium PhosphatesHypoglycemic AgentsMetforminUric AcidMetforminStone riskType 2 diabetesUrolithiasis

Identifiers

PMID41144016
PMCPMC12559097

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.